Schally AV - Search Results

1

Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.

Plonowski A, Varga JL, Schally AV, Krupa M, Groot K, Halmos G. Plonowski A, et al. Among authors: schally av. Int J Cancer. 2002 Apr 1;98(4):624-9. doi: 10.1002/ijc.10221. Int J Cancer. 2002. PMID: 11920625

2

Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.

Radulovic S, Nagy A, Szoke B, Schally AV. Radulovic S, et al. Among authors: schally av. Cancer Lett. 1992 Mar 15;62(3):263-71. doi: 10.1016/0304-3835(92)90105-5. Cancer Lett. 1992. PMID: 1317746

3

Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats.

Pinski J, Yano T, Groot K, Milovanovic S, Schally AV. Pinski J, et al. Among authors: schally av. Peptides. 1992 Sep-Oct;13(5):905-11. doi: 10.1016/0196-9781(92)90048-8. Peptides. 1992. PMID: 1336188

4

Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs.

Pinski J, Milovanovic S, Yano T, Hamaoui A, Radulovic S, Cai RZ, Schally AV. Pinski J, et al. Among authors: schally av. Proc Soc Exp Biol Med. 1992 May;200(1):49-56. doi: 10.3181/00379727-200-43393. Proc Soc Exp Biol Med. 1992. PMID: 1349189

5

Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.

Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. Yano T, et al. Among authors: schally av. Prostate. 1992;20(4):297-310. doi: 10.1002/pros.2990200405. Prostate. 1992. PMID: 1351672

6

The binding of bombesin and somatostatin and their analogs to human colon cancers.

Radulovic SS, Milovanovic SR, Cai RZ, Schally AV. Radulovic SS, et al. Among authors: schally av. Proc Soc Exp Biol Med. 1992 Jul;200(3):394-401. doi: 10.3181/00379727-200-43447. Proc Soc Exp Biol Med. 1992. PMID: 1352046

7

Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.

Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Szepeshazi K, et al. Among authors: schally av. Breast Cancer Res Treat. 1992;21(3):181-92. doi: 10.1007/BF01975001. Breast Cancer Res Treat. 1992. PMID: 1355375

8

Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.

Schally AV, Comaru-Schally AM, Gonzalez-Barcena D. Schally AV, et al. Biomed Pharmacother. 1992;46(10):465-71. doi: 10.1016/0753-3322(92)90004-q. Biomed Pharmacother. 1992. PMID: 1363977 Review.

9

Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats.

Pinski J, Yano T, Schally AV. Pinski J, et al. Among authors: schally av. Neuroendocrinology. 1992 Dec;56(6):831-7. doi: 10.1159/000126313. Neuroendocrinology. 1992. PMID: 1369591

10

Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.

Milovanovic SR, Radulovic S, Groot K, Schally AV. Milovanovic SR, et al. Among authors: schally av. Prostate. 1992;20(4):269-80. doi: 10.1002/pros.2990200403. Prostate. 1992. PMID: 1376910

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,459 results

Search Page

Filters